ArticleAdvances in radiation oncology
Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions.
Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Diagnosis and Management of Soft-Tissue Sarcomas: Current Insights.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026Review
- Partially Ablative Body Radiation Therapy Versus Standard Palliative Radiation Therapy for Locally Advanced Bulky Unresectable Sarcomas.Advances in radiation oncology · 2026Article
- Definitive proton therapy for unresectable trunk soft tissue sarcoma: a single-institution prospective registry-based cohort study.Clinical and translational radiation oncology · 2026Article
- Spatially fractionated radiotherapy versus conventional radiotherapy in the treatment of soft tissue sarcoma: A multicenter, prospective, phase II, randomized controlled clinical trial protocol.Precision radiation oncology · 2026Article
- Definitive Radiation Therapy for Ewing Sarcoma: Outcomes Based on Tumor Volume, Dose, and Fractionation.Advances in radiation oncology · 2025Article
- Article
- Article
- Advances in Radiation Oncology in Soft Tissue Sarcoma.Current oncology reports · 2025Review
- Anlotinib combined with penpulimab in the treatment of advanced adult thoracic spinal osteosarcoma: a case report.Frontiers in pharmacology · 2025Article
- Durable local control with hypofractionated radiation therapy for unresectable or metastatic melanoma.Clinical and translational radiation oncology · 2024Article
- Effect of palliative radiation dose on symptom response in metastatic sarcomas.Clinical and translational radiation oncology · 2024Article
- Mesenchymal Tumor Management: Integrating Surgical and Non-Surgical Strategies in Different Clinical Scenarios.Cancers · 2024Review
- Novel Definitive Hypofractionated Accelerated Radiation Dose-painting (HARD) for Unresected Soft Tissue Sarcomas.Advances in radiation oncology · 2024Article
- Spatially Fractionated Radiation Therapy in Sarcomas: A Large Single-Institution Experience.Advances in radiation oncology · 2024Article
- Review
- Trimodality Treatment of Extremity Soft Tissue Sarcoma: Where Do We Go Now?Current treatment options in oncology · 2023Review
- Harnessing immunomodulation during DNA damage in Ewing sarcoma.Frontiers in oncology · 2022Review
- Outcomes Following Combined Modality Treatment to the Primary Site in Select Patients With Metastatic Soft Tissue Sarcoma.Practical radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Given the relative radioresistance of sarcomas and their often large size, conventional palliative radiation therapy (RT) often offers limited tumor control and symptom relief. We report on our use of hypofractionated RT (HFRT) as a strategy to promote durable local disease control and optimize palliation. Methods and Materials: We retrospectively reviewed 73 consecutive patients with sarcoma who received >10 fractions of HFRT from 2017 to 2020. Clinical scenarios included: (1) palliative or symptomatic intent (34%), (2) an unresectable primary (27%), (3) oligometastatic disease (16%), and (4) oligoprogressive disease (23%). Results: The HFRT target was a primary tumor in 64% of patients with a median dose of 45 Gy in 15 fractions (59% ≥45 Gy). The 1-year disease-specific survival was 59%, which was more favorable for patients receiving HFRT for oligometastatic (1-year 100%) or oligoprogressive (1-year 73%) disease ( Conclusions: HFRT is an effective treatment strategy for patients with unresectable or metastatic sarcoma to provide durable LC, symptom relief, and systemic therapy breaks with limited toxic effects.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.